Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time.
Read More…
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone650-521-8000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$78.63 million
Profitability
Miscellaneous
Employees401
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions
What is Pacific Biosciences of California's stock symbol?
Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."
How were Pacific Biosciences of California's earnings last quarter?
Pacific Biosciences of California (NASDAQ:PACB) issued its quarterly earnings data on Tuesday, August, 6th. The biotechnology company reported ($0.16) earnings per share for the quarter, hitting the consensus estimate of ($0.16). The biotechnology company had revenue of $24.62 million for the quarter, compared to analysts' expectations of $22.27 million. Pacific Biosciences of California had a negative net margin of 140.68% and a negative return on equity of 106.36%. View Pacific Biosciences of California's Earnings History.
When is Pacific Biosciences of California's next earnings date?
What price target have analysts set for PACB?
3 Wall Street analysts have issued 12 month target prices for Pacific Biosciences of California's stock. Their predictions range from $6.50 to $8.00. On average, they anticipate Pacific Biosciences of California's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 46.1% from the stock's current price. View Analyst Price Targets for Pacific Biosciences of California.
What is the consensus analysts' recommendation for Pacific Biosciences of California?
What are Wall Street analysts saying about Pacific Biosciences of California stock?
Here are some recent quotes from research analysts about Pacific Biosciences of California stock:
- 1. According to Zacks Investment Research, "Pacific Biosciences exited the first quarter on a weak note. While loss per share widened, the top line missed the consensus mark. The company has been gaining ground in the MedTech space on strong Sequel performance, which saw record bookings. Meanwhile, one of Pacific Biosciences’ biggest rival — Illumina — recently announced the acquisition of the former for $8 per Pacific Biosciences share (in an all-cash transaction). Per management, the total value of the deal is approximately $1.2 billion. The agreement is expected to close by mid-2019. Reflective of these, the company has outperformed its industry in a year’s time. On the flip side, both Product and Services revenues declined year over year. Significant contraction in gross margin and rise in operating expenses are concerning. The DNA sequencing market is fraught with competition." (5/21/2019)
- 2. Cantor Fitzgerald analysts commented, "We think PACB’s long-read next-generation sequencing platform is the industry standard for deep genomic analysis in human, plant, and animal genomes, as well as RNA. The company has seen mixed revenue performance over the past three years, but we think PACB is getting close to an inflection point, which we think the Street is missing. We see the path to revenue acceleration as multifactorial. These include the launch of its 8 million ZMW SMRT cell, increased penetration of the plant and animal sequencing market, and significant sequencing cost reduction per human genome enabling PACB to become a more mainstream player in human genomics." (5/3/2019)
Has Pacific Biosciences of California been receiving favorable news coverage?
Media coverage about PACB stock has been trending negative on Monday, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Pacific Biosciences of California earned a coverage optimism score of -2.6 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Pacific Biosciences of California.
Who are some of Pacific Biosciences of California's key competitors?
Some companies that are related to Pacific Biosciences of California include Horiba (HRIBF), Accelerate Diagnostics (AXDX), Quanterix (QTRX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), Arrayit (ARYC), HTG Molecular Diagnostics (HTGM), Precipio (PRPO), Scientific Industries (SCND), BioNano Genomics (BNGO), Pressure Biosciences (PBIO), Aethlon Medical (AEMD) and PositiveID (PSID).
What other stocks do shareholders of Pacific Biosciences of California own?
Who are Pacific Biosciences of California's key executives?
Pacific Biosciences of California's management team includes the folowing people:
- Dr. Michael W. Hunkapiller, Exec. Chairman, CEO & Pres (Age 70)
- Ms. Susan K. Barnes, Exec. VP & CFO (Age 65)
- Mr. James Michael Phillips, Sr. VP of R&D (Age 68)
- Dr. Stephen Turner, Co-Founder & CTO (Age 51)
- Dr. Jonas Korlach Ph.D., Chief Scientific Officer
Who are Pacific Biosciences of California's major shareholders?
Pacific Biosciences of California's stock is owned by a number of of retail and institutional investors. Top institutional investors include Havens Advisors LLC (0.38%) and Alpine Group USVI LLC (0.26%). Company insiders that own Pacific Biosciences of California stock include James Michael Phillips, Kathy Ordonez, Michael Hunkapiller and Susan K Barnes. View Institutional Ownership Trends for Pacific Biosciences of California.
Which institutional investors are selling Pacific Biosciences of California stock?
PACB stock was sold by a variety of institutional investors in the last quarter, including Havens Advisors LLC. Company insiders that have sold Pacific Biosciences of California company stock in the last year include James Michael Phillips, Kathy Ordonez, Michael Hunkapiller and Susan K Barnes. View Insider Buying and Selling for Pacific Biosciences of California.
Which institutional investors are buying Pacific Biosciences of California stock?
How do I buy shares of Pacific Biosciences of California?
Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Pacific Biosciences of California's stock price today?
One share of PACB stock can currently be purchased for approximately $5.14.
How big of a company is Pacific Biosciences of California?
Pacific Biosciences of California has a market capitalization of $785.45 million and generates $78.63 million in revenue each year. The biotechnology company earns $-102,560,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Pacific Biosciences of California employs 401 workers across the globe.View Additional Information About Pacific Biosciences of California.
What is Pacific Biosciences of California's official website?
How can I contact Pacific Biosciences of California?
Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]
MarketBeat Community Rating for Pacific Biosciences of California (NASDAQ PACB)
MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote "Outperform" if you believe PACB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PACB will underperform the S&P 500 over the long term. You may vote once every thirty days.
